Randy Holmes-Farley
01/13/2009, 03:58 PM
I know its off topic, and for those who do not follow my real world activities, just ignore this thread, but for those who do, this is what I've been spending a lot of my time on for the past few years...
My previously approved compounds for phosphate binding in people are Renagel and Renvela, but we just filed for a new phosphate binding therapy:
http://www.businesswire.com/portal/site/cnnmoney/index.jsp?ndmViewId=news_view&newsId=20090113006042&newsLang=en&ndmConfigId=1000618&vnsId=33
from it:
Genzyme’s Cardiometabolic and Renal segment generated revenue of $956 million in 2008, a 15 percent increase over $833 million in 2007, and is on track to generate approximately $1.4 billion annually by 2011. Key drivers will include the sustained growth of the company’s sevelamer therapies Renagel® (sevelamer hydrochloride) and Renvela. The increasing use of these products globally and the anticipated expansion of Renvela’s U.S. indication to include the treatment of patients with chronic kidney disease who are not on dialysis are expected to act as principal catalysts for this growth.
Fourth-quarter sales of sevelamer were $169 million, compared with $166 million in the previous fourth quarter. For the year, sales increased 13 percent to $678 million, compared with $603 million the year before.
Genzyme has filed an IND for an advanced phosphate binder (APB) and expects to begin a phase 2/3 trial this year. The APB is designed to more effectively bind phosphate for a substantial improvement in potency over existing therapies while maintaining all of the benefits of sevelamer.
My previously approved compounds for phosphate binding in people are Renagel and Renvela, but we just filed for a new phosphate binding therapy:
http://www.businesswire.com/portal/site/cnnmoney/index.jsp?ndmViewId=news_view&newsId=20090113006042&newsLang=en&ndmConfigId=1000618&vnsId=33
from it:
Genzyme’s Cardiometabolic and Renal segment generated revenue of $956 million in 2008, a 15 percent increase over $833 million in 2007, and is on track to generate approximately $1.4 billion annually by 2011. Key drivers will include the sustained growth of the company’s sevelamer therapies Renagel® (sevelamer hydrochloride) and Renvela. The increasing use of these products globally and the anticipated expansion of Renvela’s U.S. indication to include the treatment of patients with chronic kidney disease who are not on dialysis are expected to act as principal catalysts for this growth.
Fourth-quarter sales of sevelamer were $169 million, compared with $166 million in the previous fourth quarter. For the year, sales increased 13 percent to $678 million, compared with $603 million the year before.
Genzyme has filed an IND for an advanced phosphate binder (APB) and expects to begin a phase 2/3 trial this year. The APB is designed to more effectively bind phosphate for a substantial improvement in potency over existing therapies while maintaining all of the benefits of sevelamer.